Cheuk Hong Leung

The University of Texas MD Anderson Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Table S1. Patient and tumor characteristics. Table S2. Representativeness of study participants. Table S3. Clinical and histopathologic characteristics of individual patients. Table S4. Treatment related adverse events that occurred after first dose. Table S5. Adverse events related to immune checkpoint blockade. Table S6. Serious adverse events.

Year:

2025

In a phase II trial, patients with local-regionally advanced human papillomavirus–positive oropharyngeal carcinoma ( n = 35) received ipilimumab (anti-CTLA4) and nivolumab (anti–PD-1) as induction immunotherapy and concurrently with radiotherapy (NCT03799445). Coprimary endpoints included 6-month complete metabolic response rate (94%) and 2-year progression-free survival (84%). Induction yielded a 46% major histopathologic response rate. Single-cell profiling revealed responders had higher baseline intratumoral CD8 + T cells with a tumor-reactive, tissue-resident memory (TRM) phenotype and a treatment-related decrease in effector regulatory T (eTreg) cells. The eTreg decrease correlated with CD8 + T-cell clonotype transitioning from TRM to effector memory and IFNG + effector cells. In nonresponders, clonotypes transitioned to exhausted TRM and proliferating cells. Multivariable regression modeling determined that the baseline feature most associated with reduction in tumor viability was the proportion of FCGR3A -expressing NK cells, which are capable of ipilimumab-dependent depletion of CTLA4 high eTregs. eTreg depletion may be critical for major response to induction dual immune checkpoint blockade (ICB). Significance: The relative contributions of CD28 costimulation restoration versus Treg depletion to clinical response to CTLA4 ICB is a matter of considerable controversy. In this study, we provide compelling data that eTreg depletion is critical to tumor clearance in patients treated with dual PD-1 and CTLA4 ICB.

Year:

2025

Fig. S1. Patient disposition and characteristics. Fig. S2. Timing of OI biopsy collection did not correlate with response. Fig. S3. Major cell types identified in the tumor immune microenvironment. Fig. S4. CD4+ T cells identified in the tumor immune microenvironment. Fig. S5. Effector Treg cells in the HPV-positive OPC TIME highly express activation markers. Fig. S6. Treatment-induced changes in Treg proportions and clonotype frequencies. Fig. S7. CD8+ T cells in MHRs have different transcriptional programs vs those in nMHRs. Fig. S8. CD8+ T cells identified in the tumor immune microenvironment. Fig. S9. T cell clusters did not vary by anatomic site. Fig. S10. TRM CD8+ T cells had high expression of tumor-reactive, cytotoxic and checkpoint genes. Fig. S11. Fluorescent imaging of antigen-experienced, memory CD8+ T cells in baseline tumors. Fig. S12. Clonality of CD4+ T-cell TCR repertoire. Fig. S13. CD8+ T-cell TCR repertoire clonality and dynamics. Fig. S14. Phenotypes of treatment-altered CD8 clonotypes varied by response. Fig. S15. Predominant phenotypes of treatment-responsive CD8+ T-cell clonotypes. Fig. S16. Identification of HPV-specific TCRs. Fig. S17. NK cells that express Fc gamma receptor IIIa (CD16) are more activated than those that do not. Fig. S18. Increase in proportion of Effector1(IFNG+) cells associated with reduction in tumor viability.

Year:

2025

Accumulating evidence indicates that the gut microbiome influences cancer progression and therapy. We recently showed that progressive changes in gut microbial diversity and composition are closely coupled with tobacco-associated lung adenocarcinoma in a human-relevant mouse model. Furthermore, we demonstrated that the loss of the antimicrobial protein Lcn2 in these mice exacerbates protumor inflammatory phenotypes while further reducing microbial diversity. Yet, how gut microbiome alterations impinge on lung adenocarcinoma development remains poorly understood. In this study, we investigated the role of gut microbiome changes in lung adenocarcinoma development using fecal microbiota transfer and delineated a pathway by which gut microbiome alterations incurred by loss of Lcn2 fostered the proliferation of proinflammatory bacteria of the genus Alistipes , triggering gut inflammation. This inflammation propagated systemically, exerting immunosuppression within the tumor microenvironment, augmenting tumor growth through an IL6-dependent mechanism and dampening response to immunotherapy. Corroborating our preclinical findings, we found that patients with lung adenocarcinoma with a higher relative abundance of Alistipes species in the gut showed diminished response to neoadjuvant immunotherapy. These insights reveal the role of microbiome-induced inflammation in lung adenocarcinoma and present new potential targets for interception and therapy.

Year:

2024

Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alterations: (1) somatic BRCA 1/2, (2) other homologous recombination repair pathway, (3) PTEN and (4) germline BRCA1/2 . The primary endpoint was a clinical benefit rate (CBR): complete response, partial response or stable disease ≥24 weeks. 79 patients with a median of 4 lines of therapy were enrolled. CBR for cohorts 1–4 were: 32.5%, 19.7%, 9.4% and 30.6%, respectively. PTEN mutations correlated with reduced survival and a trend towards shorter time to progression.Talazoparib demonstrated clinical benefit in selected DDR-altered patients. PTEN mutations/loss patients derived limited clinical benefit. Further study is needed to determine whether PTEN is prognostic or predictive of response to PARP inhibitors.

Year:

2024

Collaborators (41)

Neil Gross

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kanwal Raghav

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gordon Mills

Professor

Oregon Health & Science University

UNITED STATES
View details

Jay Paul Reddy

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

matthew ross

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Michael A. Curran

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michelle D. Williams

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kristi Hoffman

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Aung Naing

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Baohua Sun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Vivek Subbiah

Professor of Medicine and of Pediatrics

Stanford University

UNITED STATES
View details

Apostolia M. Tsimberidou

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Joe Dan Dunn

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Edwin Roger Parra

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Akagi Keiko

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jack Phan

Physician/Associate Professor

MD Anderson Cancer Center

UNITED STATES
View details

Junya Fujimoto

Professor and Chair

Hiroshima University Hospital

JAPAN
View details

Renata Ferrarotto

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sarina Piha-Paul

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Miriam Lango

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Maura L. Gillison

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Qingnan Liang

Assistant Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Robert Jenq

Professor

City Of Hope National Medical Center

UNITED STATES
View details

Jason Johnson

Section Chief, Neuroradiology / Associate Professor

Yale University

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nils Rudqvist

Assistant Professor (joint appointment)

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Seyed Javad Moghaddam

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shan He

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Meng Li

Assistant Professor

Rice University

UNITED STATES
View details

Shengbin Ye

Assistant Professor of Instruction

Northwestern University

UNITED STATES
View details

Suyu Liu

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nadim Ajami

Executive Director

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Humam Kadara

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Joseph Petrosino

Department Chair

Baylor College of Medicine

UNITED STATES
View details

Jaffer A. Ajani

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Clifton D Fuller

Professor (Tenured)

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details